Cerebrolysin is a combination of peptides and neurotrophins for enhancing the regeneration of neurons, neural plasticity, and neural protection during neurological illnesses, such as dementia and traumatic brain injuries. It is a neuropeptide drug formed from a series of biochemical and enzymatic reactions on porcine brain proteins. The ultimate product that is formed after a series of reactions has a low molecular weight and increased ability to cross the blood-brain barrier.
After the administration of Cerebrolysin, the neuronal functions and different neuronal conditions show a significant improvement. Here are the principal components of Cerebrolysin:
- Nerve growth factor (NGF)
- Brain-derived neurotrophic factor (BDNF)
- Glial cell line-derived neurotrophic factor (GDNF)
- Ciliary neurotrophic factor (CNTF)
How Does Cerebrolysin Work?
Cerebrolysin work in several ways that include the following:
- Promoting the growth of brain cells and their functional efficacy.
- Prevention of brain death due to ischemia and many other harmful pathological mechanisms.
- Increase learning and thinking capacity by improving connection among brain cells and with other body cells.
- Enhancing brain energy by increasing the production of protein in brain cells and uptake of glucose by brain cells.
- Reduction in amyloid deposition, reactivation of astrocytes, and brain death.
- Decreasing inflammatory reactions in the brain.
Clinical Uses of Cerebrolysin:
According to a recent systemic review, dementia can benefit from Cerebrolysin. The most significant effects of Cerebrolysin were documented in patients with vascular dementia. It is a type of dementia caused by the compromise of blood supply to the brain. This disease results in a mixture of symptoms associated with dementia, Alzheimer’s disease, and stroke.
Intravenous administration of Cerebrolysin can enhance the cognitive abilities in patients with dementia. Cerebrolysis is administered as a daily dose for a different time period depending on the duration and severity of the disease. In a clinical trial, the cognitive function of the patients was assessed after Cerebrolysin administration with the help of different techniques such as arithmetic, recalling, and other abilities. All the assessments determined significant improvement.
However, there was limited evidence regarding the benefits associated with the overall clinical condition of the patients. Cerebrolysin administration shows no serious side effects and is well tolerated in patients with dementia.
Traumatic Brain Injury:
Traumatic brain injuries are a significant cause of death and severe disabilities because of a lack of interventions in the field of neurological trauma. However, Cerebrolysin has shown significant results in patients with a traumatic brain injury which shows comparable efficacy to other conventional treatments and is also more effective than other treatments in some aspects.
According to researches, intravenous Cerebrolysin shows improved functional recovery in patients with a severe traumatic injury. In mild to moderate injury, Cerebrolysin showed complete recovery. However, several factors affect the efficacy of Cerebrolysin, which include dosage and duration of therapy, the interval between trauma and treatment, and grade of injury.
Cerebrolysin can benefit patients with mild to severe brain injuries. After severe traumatic brain injury, Cerebrolysin administration results in decreased mortality rate, better outcomes, and improved functionality of the affected area. In severe brain injuries, Cerebrolysin has shown more efficacy than other pharmacological agents.
According to systemic research conducted regarding the efficacy of Cerebrolysin in traumatic brain injury showed that it can enhance cognitive abilities and protect motor dysfunction associated with traumatic brain injury. Recent research conducted on 32 patients showed that Cerebrolysin can improve long-term memory in patients after traumatic brain injury.
A stroke occurs as a result of blockage of the vessel supplying the brain, which results in the death of neurons and other brain cells supplied by that vessel. Cerebrolysin can improve cognition and motor functions in patients with stroke. There is strong evidence that patients who were treated with Cerebrolysin have increased and faster recovery rates.
A clinical trial performed on more than 200 patients regarding the efficacy of Cerebrolysin in patients with stroke showed that it can improve cognition and motor function in post-stroke patients, which can be determined by several lab tests. In this clinical trial, patients were administered with Cerebrolysin, 72 hours after stroke and continued for 21 days.
Side Effects of Cerebrolysin:
Clinical studies showed that Cerebrolysin is a very safe product and well-tolerated in most patients. No evidence of allergy or anaphylactic reaction has been documented regarding Cerebrolysin. However, minimal side effects can occur which are usually temporary and resolve within 2-3 days. Common side effects include the following:
- Headache, confusion, anxiety
- Dizziness and sweating
- Agitated behavior
- Burning sensation in the stomach
- Weight loss
- Diarrhea and Nausea
- Irritation on injection site
Optimum doses of Cerebrolysin are safe and may cause side effects as listed above. However, toxic doses can result in severe palpitations and vomiting.
Where to buy online Cerebrolysin:
Buy Cerebrolysin at RUPharma.com [link https://rupharma.com/cerebrolysin] with delivery to United States, Canada, Europe, Australia and Asia.
Plosker, G. L., & Gauthier, S. (2009). Cerebrolysin: a review of its use in dementia. Drugs & aging, 26(11), 893–915. https://doi.org/10.2165/11203320-000000000-00000
Ghaffarpasand, F., Torabi, S., Rasti, A., Niakan, M. H., Aghabaklou, S., Pakzad, F., Beheshtian, M. S., & Tabrizi, R. (2018). Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis. Neuropsychiatric disease and treatment, 15, 127–135. https://doi.org/10.2147/NDT.S186865
Brainin M. (2018). Cerebrolysin: a multi-target drug for recovery after stroke. Expert review of neurotherapeutics, 18(8), 681–687. https://doi.org/10.1080/14737175.2018.1500459